Table 4.
Concomitant medications
| Total (N = 41) n (%) | |
|---|---|
| Number of patients with any concomitant medication | 40 (97.56) |
| WHO ATC 2nd level/preferred term | |
| Anti-Parkinson drugs | 1 (2.44) |
| Anticholinergic agents | 1 (2.44) |
| Antiepileptics | 4 (9.76) |
| Antiepileptics | 1 (2.44) |
| Gabapentin | 2 (4.88) |
| Topiramate | 2 (4.88) |
| Antihistamines for systemic use | 1 (2.44) |
| Antihistamines | 1 (2.44) |
| Psychoanaleptics | 19 (46.34) |
| Antidepressants | 19 (46.34) |
| Psycholeptics | 37 (90.24) |
| Anxiolytics | 10 (24.39) |
| Aripiprazole | 4 (9.76) |
| Benzodiazepine derivatives | 17 (41.46) |
| Brexpiprazole | 3 (7.32) |
| Cariprazine | 1 (2.44) |
| Clotiapine | 2 (4.88) |
| Clozapine | 7 (17.07) |
| Haloperidol | 4 (9.76) |
| Olanzapine | 7 (17.07) |
| Paliperidone | 1 (2.44) |
| Pipamperone | 1 (2.44) |
| Psychotropic agents | 24 (58.54) |
| Quetiapine | 9 (21.95) |
| Risperidone | 6 (14.63) |
Concomitant medications were defined as therapies ending or ongoing after the start of study treatment
Percentages were computed on eligible population
ATC Anatomical Therapeutic Class